The global Scleroderma Therapeutics market size is expected to be worth around US$ 2.10 billion by 2028, according to a new report by Vision Research Reports.
The global Scleroderma Therapeutics market size was valued at US$ 1.65 billion in 2020 and is anticipated to grow at a CAGR of 6.06% during forecast period 2021 to 2028.
The market growth is credited to the availability of various therapies used off-label, such as small molecule therapies including branded, generics, and OTC drugs.
The mix of several indications and drug classes engenders a fragmented market with multiple players. Roche is the dominant company with biologic immunosuppressants, Actemra/RoActemra, Cellcept, and Rituxan contributing majorly to the company’s share. Pfizer and Eli Lilly are the key companies in the market. Over the forecast period, new entrants including Boehringer Ingelheim, Corbus Pharmaceuticals, and Fibrocell will marginally displace the share of established firms in this market.
The on-label market is in the development phase. Supplemental indication approval is one of the most common strategies adopted by market participants. For example, riociguat by Bayer was previously used for PAH and currently, it is under clinical trials for the treatment of SSc-related digital ulcers. There are several other pharmaceutical companies following suit as this strategy favors the pharmaceutical industry in offsetting high development costs and in reaping larger benefits from one molecule already developed and present in the market.
On the basis of drug class, the market is segmented into immunosuppressors, Phosphodiesterase 5 Inhibitors - PHA, endothelin receptor antagonists, prostacyclin analogs, calcium channel blockers, analgesics, and others. Without a curative therapy for this disease, an expansive range of drug classes are prescribed to provide symptomatic relief. Immunosuppressants hold prominence as this class contains several biologics from established players such as Roche. Biologics and small molecule immunosuppressants are a growing segment with several pipeline drugs for scleroderma focusing on this class.
Novel therapies including Lenabasum and Ofev are expected to enter within the forecast period that is classed under ‘other drug classes’. PDE-5 inhibitors market by drug classes is facing headwinds due to the patent expiration of Revatio that bring down the revenue. ERAs remain in focus as this class of drugs mostly includes branded therapies and due to their use in the treatment of the indication with high incidence i.e. PAH.
Based on indication, the scleroderma therapeutics market is categorized into localized and systemic scleroderma. The indications falling under systemic scleroderma include SSc-induced symptoms and conditions that range from interstitial lung disease to pulmonary arterial hypertension. Systemic indications account for the majority of share due to the use of high-priced immunosuppressants.
Localized scleroderma currently holds a small share in this market but is expected to grow over the forecast period with the expected launch of a first-in-class therapy, FCX-013 by Fibrocell. Fibrocell’s FCX-013 holds the orphan drug and fast track designation and if approved, it would be the first gene therapy for localized scleroderma. This treatment aims to arrest the fibrosis in the early stages of the disease. Lenabasum by Corbus Pharmaceuticals is the first oral therapy with high curative potential targeting diffuse cutaneous systemic sclerosis that is associated with a high burden of comorbidities.
North America was the dominant regional market in 2020. Access to recently developed immunosuppressants coupled with favorable reimbursement scenario is the key revenue driver. Europe trails with a lower share as compared to the U.S. majorly due to higher use of generics and biosimilars for off-label treatment of scleroderma.
F. Hoffman La-Roche Ltd.; Bristol-Myers Squibb Company; Celgene Corp.; arGentis Pharmaceuticals, LLC; Bayer AG; Boehringer Ingelheim International GmbH; Akashi Therapeutics; Prometic Life Sciences, Inc.; Emerald Health Pharmaceuticals; Kadmon Holdings, Inc.; Seattle Genetics, Inc.; Cytori Therapeutics, Inc.; Fibrocell Science, Inc.; Chemomab; Corbus Pharmaceuticals Holdings, Inc.; and Genkyotex.
Drug Class Outlook
Phosphodiesterase 5 Inhibitors - PHA
Endothelin Receptor Antagonists
Calcium Channel Blockers
The Scleroderma Therapeutics market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Scleroderma Therapeutics market for the base year 2020 and the forecast between 2021 and 2028. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Scleroderma Therapeutics market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Scleroderma Therapeutics market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Scleroderma Therapeutics market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Scleroderma Therapeutics capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Scleroderma Therapeutics by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Scleroderma Therapeutics market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2028. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Scleroderma Therapeutics market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Scleroderma Therapeutics market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Scleroderma Therapeutics industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Scleroderma Therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Scleroderma Therapeutics market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Scleroderma Therapeutics market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Scleroderma Therapeutics market. These factors have benefited the growth of the global market for Scleroderma Therapeutics. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Scleroderma Therapeutics. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Scleroderma Therapeutics are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Telemedicine Market (By Component: Product, Services; By Technology: Store and forward, Real time, Others; By Application: Teleradiology, Telepsychiatry; By Delivery Mode; By Type: Tele-hospital, Tele-home; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Telehealth Market (By Type: Hardware, Software, & Services; By Application: Telemedicine, Patient Monitoring, Continuous Medical Education, & Others; By Modality: Store-and-Forward, Real-Time, & Remote Patient Monitoring; By Mode of Delivery: Cloud-Based & On-Premises; By End-Users: Healthcare Facilities, Homecare, & Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Ophthalmology Surgical Devices Market (By Product: Cataract Surgery Devices (Intraocular Lenses (IOLs), Ophthalmic Viscoelastic Devices), Glaucoma Surgery Devices, Vitreoretinal Surgery Devices, Refractive Surgery Devices; By End use: Hospitals, Ambulatory Surgical Centers, Ophthalmic Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Cell Culture Market (By Product: Instrument and Consumables; By Application: Stem Cell Technology, Cancer Research, Drug Screening & Development, Tissue Engineering & Regenerative Medicine and Others; By End User: Research Institutes, Pharmaceutical &x Biotechnology Companies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...
Microscopy Devices Market (By Product Type: Optical Microscopy, Scanning Probe Microscopy, Electron Microscopy, Microscopy Accessories; By Application: Cell and Molecular Biology, Pharmacology and Toxicology, Clinical Pathology and Diagnostics, Surgery, Biomedical Engineering, Neuroscience; By End use: Hospitals, Diagnostic Laboratories, Ambulatory Surgery Centers (ASCs), Physician Offices, and Academic & Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030Read more...